SCHEMBL20337927

SCHEMBL20337927

CC(C)(C)[Si](C)(C)OCCn1ccc2c(OCc3ccccc3)cccc21

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ HTR6 P50406 4/20 0.45
▸ MCL1 Q07820 4/20 0.44
▸ ROCK1 Q13464 3/20 0.44
▸ BCL2 P10415 2/20 0.44
▸ MAPT P10636 1/20 0.39
▸ MAPK1 P28482 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ BRD4 O60885 2/20 0.38
▸ BAD Q92934 1/20 0.37
▸ DUT P33316 1/20 0.37
▸ PPARG P37231 1/20 0.37
▸ PPARA Q07869 1/20 0.36
▸ BCHE P06276 1/20 0.36
▸ MAPK14 Q16539 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADORA2A P29274 1/20 0.36
▸ ADORA1 P30542 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20348541 0.78 HTR2C (0.46) MCL1MAPTDUT
SCHEMBL20337987 0.77 HTR2C (0.53) HTR6MCL1BADDUTPPARG
SCHEMBL2262948 0.77 DUT (0.42) MAPTDUT
SCHEMBL7958584 0.77 HTR6 (0.50) HTR6MCL1ROCK1BCL2MAPT
SCHEMBL6030279 0.77 DUT (0.51) HTR6MCL1BCL2MAPTMAPK1
SCHEMBL4323501 0.77 HTR6 (0.52) HTR6MCL1ROCK1BCL2MAPT
SCHEMBL23956093 0.76 HTR2C (0.56) HTR6MCL1ROCK1BCL2MAPT
SCHEMBL7962451 0.76 HTR6 (0.47) HTR6MCL1ROCK1BCL2MAPT
SCHEMBL18049242 0.75 HTR6 (0.67) HTR6MCL1ROCK1BCL2MAPT
SCHEMBL20337898 0.74 HTR6 (0.48) HTR6MCL1ROCK1BCL2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2018-07-05 — — US disclosed
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF PHARMAKEA INC (US) 2018-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186755-A1 LYSYL OXIDASE-LIKE 2 INHIBITORS AND USES THEREOF LOXL2, LOXL1, LOX HTR6 2732/4885MCL1 1399/4885ROCK1 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback